IL6 and myelodysplastic syndrome: While Siltuximab (CNTO 328; IL-6-blocking antibody) has been proposed as a treatment option for myelodysplastic syndrome (MDS) and multiple myeloma and is FDA-approved for the treatment of idiopathic multicentric Castleman’s disease (140), Siltuximab in the AML setting has so far only been investigated in an AML xenograft mouse model that mimics end-stage BM failure.